Reviewer's report

Title: Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk women and women with breast cancer

Version: 3 Date: 7 September 2006

Reviewer: Gillian Mitchell

Reviewer's report:

General  

--------------------------------------------------------------------------------

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

I still have concerns about the interpretation of the PGE2 results in NAF and plasma (page 9). The statement that Celecoxib significantly decreased PGE2 levels in NAF of high risk women needs clarification, as it was only observed in the postmenopausal high risk group. In the premenopausal high risk group, levels actually rose after Celecoxib treatment (table 4). As a consequence the 2nd paragraph of the discussion on page 11 will need adjustment. Also, "NAF PGE2 levels are higher in pre than in post menopausal women" (page 9) The p values stated in the text (0.0083 and 0.0023) are different from those in table 4 (0.04 and 0.003)

--------------------------------------------------------------------------------

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)

--------------------------------------------------------------------------------

Discretionary Revisions (which the author can choose to ignore)

What next?: Unable to decide on acceptance or rejection until the authors have responded to the major compulsory revisions

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No

Declaration of competing interests:

I declare I have no competing interests